NovoCure (NVCR) vs Tandem Diabetes Care (TNDM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tandem Diabetes Care (TNDM) has outperformed NovoCure (NVCR) over the past year, gaining 2.2% versus a loss of 0.9%. Over five years, NVCR leads with a -87.3% price change compared with -87.5% for TNDM. NovoCure is the larger company by market cap ($1.66 billion vs $1.09 billion), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVCR | TNDM |
|---|---|---|
| Share price | $14.22 | $15.68 |
| Market cap | $1.66B | $1.09B |
| 1-day change | -3.00% | -1.04% |
| YTD return | +9.98% | -28.69% |
| 1-year return | -0.91% | +2.18% |
| 5-year return | -87.33% | -87.50% |
| Forward P/E | — | 98.61 |
| EPS (TTM) | $-1.30 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $655.35M | — |
| Revenue growth (YoY) | +8.28% | — |
| Net income (latest FY) | $-136.23M | — |
| Gross margin | 74.54% | — |
| Operating margin | -23.47% | — |
| Net margin | -20.79% | — |
| 52-week high | $21.45 | $29.65 |
| 52-week low | $9.82 | $12.26 |
| Distance from 52-week high | -33.71% | -47.13% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +88.89% | +77.74% |
| Average volume | 1.42M | 2.01M |
| Shares outstanding | 116.45M | 69.58M |
| Employees | 1,605 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NovoCure
NVCR stock →NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Health Care · Medical/Dental Instruments · 1,605 employees
About Tandem Diabetes Care
TNDM stock →Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally.
Health Care · Medical/Dental Instruments · 2,500 employees
NVCR vs TNDM FAQ
Which is bigger, NovoCure or Tandem Diabetes Care?
NovoCure (NVCR) is larger, with a market capitalization of $1.66B compared with $1.09B for Tandem Diabetes Care (TNDM).
Which stock has performed better over the past year, NVCR or TNDM?
TNDM returned +2.18% over the past 12 months, compared with -0.91% for NVCR (price return, excluding dividends). Past performance does not predict future results.
Are NovoCure and Tandem Diabetes Care in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.